As the One Big Beautiful Bill approaches final approval, life sciences leaders are closely watching what it could mean for research, regulation, and commercialization. With momentum building, understanding the bill’s implications is critical for strategic planning across biotech, pharma, medtech, and beyond. Join us for a clear, sector-specific breakdown of the bill’s key provisions, anticipated timelines, and potential impact on everything from clinical development to supply chain operations. We’ll explore what’s likely to change, what remains uncertain, and what your...

Read More Read More